- With Mayo Clinic psychiatrist
David Mrazek, M.D.
read biographyclose windowBiography of
David Mrazek, M.D.
David Mrazek, M.D.
Dr. David A. Mrazek is chair of the Department of Psychiatry and Psychology at Mayo Clinic, Rochester, Minn., and a professor of psychiatry at College of Medicine, Mayo Clinic. Dr. Mrazek has developed a federally funded psychiatric pharmacogenomics research program and implemented clinical psychiatric pharmacogenomics services at Mayo Clinic.
He has received numerous awards including the Award for Creativity in Psychiatric Education from the American College of Psychiatrists and the Agnes Purcell McGavin Award for Distinguished Career Achievement in Child and Adolescent Psychiatry from the American Psychiatric Association. He currently serves as chairman of the board of the American Board of Psychiatry and Neurology.
Dr. Mrazek has focused his current efforts on using pharmacogenomics testing to improve clinical care. One of his specific goals is to decrease the risks of taking psychiatric medications.
Latest entries
- Depression sometimes shifts to bipolar disorder
Jan. 21, 2012
- Antidepressant use soaring among Americans 12 and over
Dec. 7, 2011
- Transcranial magnetic stimulation offers hope treating depression
Oct. 19, 2011
- New antidepressant offers hope
Sept. 3, 2011
- Sorting out the evidence for antidepressants
July 22, 2011
About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Depression blog
-
Jan. 17, 2009
FDA antidepressant warnings: Use caution when starting medication
By David Mrazek, M.D.
| Need more help? |
|
The Food and Drug Administration (FDA) sometimes releases warnings on medications when a medication previously approved is shown to be potentially harmful. It's possible for new side effects and other problems to come up after medications are approved and been on the market for awhile. Once a warning is issued (if the medication is not removed from the market), close monitoring continues. Why am I writing about this subject? In 2004, a warning was issued regarding antidepressant medication use in children and adolescents. This warning was later expanded to include young adults (ages 18 to 24). There was concern that antidepressants might increase the risk of suicide in these age groups (this risk was not found in those older than 24).
The FDA specifically advised:
- Anyone who starts being treated with antidepressant medicines, particularly those being treated for depression, should be watched closely for worsening of depression and for increased suicidal thinking or behavior.
- Close observation of adults may be especially important when antidepressant medications are started for the first time or when doses for their antidepressant medications have been changed.
- Adults whose symptoms worsen while being treated with antidepressants, including an increase in suicidal thinking or behavior, should be evaluated by their health care professional.
Please take the time to review potential side effects with your health care provider. It's important that you are well informed about both your illness and treatment options, including risks, benefits and alternatives.
7 comments posted